News
Public · Published
Canaccord Genuity maintains DexCom at Buy, raises price target to $97 from $90
Canaccord Genuity kept its Buy rating on DexCom and raised its price target to $97 from $90. The new target is 7.8% higher than its previous target and implies 17.9% upside from DexCom's Oct. 30 closing price of $82.29.
Published:
Updated:
What happened
Canaccord Genuity kept its Buy rating on DexCom and raised its price target to $97 from $90. The new target is 7.8% higher than its previous target and implies 17.9% upside from DexCom’s Oct. 30 closing price of $82.29.
Confirmed
Global impact / market context
The higher target signals greater expected share-price appreciation from Canaccord, but it does not change the firm’s Buy rating. If investors act on the more optimistic view, their buying or selling could influence DexCom’s share price; the article reports no change to the company’s operations or finances.
Analyst inference
Analyst views remain spread out: the five recent price targets listed range from $85 to $120, while Canaccord’s new target is $97. This gap shows that analysts differ in their expectations, so one higher target does not represent a shared forecast.
Confirmed
What to watch
- Check whether Canaccord publishes further changes to its rating or $97 target; a later revision would show whether its more optimistic estimate is sustained. Analyst inference
- Compare future analyst targets with the listed $85–$120 range; targets moving closer together or farther apart would indicate changing agreement about DexCom’s shares. Analyst inference
- Watch whether DexCom’s share price moves toward or away from Canaccord’s $97 target; the article gives $82.29 as the Oct. 30 close. Analyst inference
Evidence
- Original source link unavailable